Mirae Asset Global Investments Co. Ltd. Purchases 403 Shares of Xenon Pharmaceuticals Inc. $XENE

Mirae Asset Global Investments Co. Ltd. increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 15.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,964 shares of the biopharmaceutical company’s stock after acquiring an additional 403 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Xenon Pharmaceuticals were worth $93,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC bought a new position in shares of Xenon Pharmaceuticals in the 2nd quarter worth about $25,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Xenon Pharmaceuticals during the first quarter valued at approximately $30,000. GF Fund Management CO. LTD. increased its stake in shares of Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 351 shares in the last quarter. Vident Advisory LLC increased its position in Xenon Pharmaceuticals by 21.4% during the 1st quarter. Vident Advisory LLC now owns 6,574 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 1,161 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new position in Xenon Pharmaceuticals during the 1st quarter valued at approximately $298,000. 95.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

XENE has been the subject of a number of analyst reports. Wedbush raised their price objective on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, August 12th. Chardan Capital restated a “buy” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, October 7th. Bloom Burton upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, October 7th. Royal Bank Of Canada restated an “outperform” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company began coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, September 3rd. They set an “overweight” rating and a $48.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $53.67.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,004,000.00. Following the completion of the sale, the chief executive officer directly owned 31,302 shares in the company, valued at approximately $1,257,088.32. The trade was a 44.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Trading Down 4.0%

NASDAQ:XENE opened at $39.64 on Monday. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.00. The company has a market cap of $3.06 billion, a PE ratio of -11.17 and a beta of 1.14. The company has a 50 day simple moving average of $37.63 and a two-hundred day simple moving average of $34.21.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the prior year, the company earned ($0.75) earnings per share. Research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.